AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26568577 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation containing Lactobacillus casei (PRO)
Number of subjects: 8
Study 26568577 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 8
Study 24798768 — intervention group
Group type: EXPERIMENTAL
Intervention: EFV-based HAART regimen
Number of subjects: 45
Study 24798768 — intervention group
Group type: EXPERIMENTAL
Intervention: LPV/r-based HAART regimen
Number of subjects: 45
Study 24798768 — intervention group
Group type: COMPARATOR
Intervention: non-HAART group
Number of subjects: 45
Study 22414827 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoject syringe with 27‐gauge needle
Number of subjects: 30
Study 22414827 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive ultrasonic irrigation (PUI) with IrriSafe tip
Number of subjects: 30
Study 22414827 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoVac system
Number of subjects: 30
Study 22414827 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive ultrasonic irrigation (PUI)
Number of subjects: 30
Study 20373908 — intervention group
Group type: EXPERIMENTAL
Intervention: I-neb AAD System with Target Inhalation Mode (TIM)
Number of subjects: 12
Study 20373908 — intervention group
Group type: COMPARATOR
Intervention: I-neb AAD System with Tidal Breathing Mode (TBM)
Number of subjects: 12
Study 18575223 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene 0.3% gel
Number of subjects: 551
Study 16019647 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-source interference task (MSIT)
Number of subjects: 0
Study 16019647 — intervention group
Group type: EXPERIMENTAL
Intervention: Flanker interference
Number of subjects: 0
Study 16019647 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial interference
Number of subjects: 0
Study 12449165 — intervention group
Group type: EXPERIMENTAL
Intervention: MPA (30 mg b.i.d.)
Number of subjects: 17
Study 12449165 — intervention group
Group type: EXPERIMENTAL
Intervention: ACET (250 mg b.i.d.)
Number of subjects: 17
Study 12449165 — intervention group
Group type: EXPERIMENTAL
Intervention: MPA/ACET
Number of subjects: 17
Study 12449165 — intervention group
Group type: EXPERIMENTAL
Intervention: MPA
Number of subjects: 17
Study 10211236 — intervention group
Group type: EXPERIMENTAL
Intervention: General practice teaching
Number of subjects: 225
Study 10211236 — intervention group
Group type: COMPARATOR
Intervention: Teaching hospital
Number of subjects: 225
Study 8523872 — intervention group
Group type: EXPERIMENTAL
Intervention: Carmeda BioActive Surface coated circuit
Number of subjects: 67
Study 8523872 — intervention group
Group type: EXPERIMENTAL
Intervention: Duraflo II bonded heparin coated circuit
Number of subjects: 67
Study 8523872 — intervention group
Group type: COMPARATOR
Intervention: Uncoated circuit (control for Carmeda)
Number of subjects: 67
Study 8523872 — intervention group
Group type: COMPARATOR
Intervention: Uncoated circuit (control for Duraflo II)
Number of subjects: 67
Study 1686197 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel anxiolytic/hypnotic compound
Number of subjects: 0
Study 1686197 — intervention group
Group type: COMPARATOR
Intervention: Zolpidem
Number of subjects: 0
Study 1686197 — intervention group
Group type: COMPARATOR
Intervention: Triazolam
Number of subjects: 0
Study 7145555 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose split-product vaccine (SPV) containing 7, 7, and 60 micrograms of hemagglutinins (HA)
Number of subjects: 80
Study 7145555 — intervention group
Group type: COMPARATOR
Intervention: Standard dose split-product vaccine (SPV) containing 7, 7, and 7 micrograms of HA
Number of subjects: 80
Study 7145555 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose split-product vaccine (SPV)
Number of subjects: 80
Study 7145555 — intervention group
Group type: COMPARATOR
Intervention: Standard dose split-product vaccine (SPV)
Number of subjects: 80
Study 7145555 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated matched sibling control subjects
Number of subjects: 80
Study 31478938 — intervention group
Group type: COMPARATOR
Intervention: Nurse-controlled sedation (NCS) with midazolam
Number of subjects: 150
Study 31478938 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled sedation (PCS) with propofol (PCS-MS group)
Number of subjects: 150
Study 31478938 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled sedation (PCS) with propofol (PCS-G group)
Number of subjects: 150
Study 30529442 — intervention group
Group type: EXPERIMENTAL
Intervention: PROMIS Pain Interference scales
Number of subjects: 759
Study 30529442 — intervention group
Group type: COMPARATOR
Intervention: Legacy pain measures (Brief Pain Inventory Interference scale; Pain, Enjoyment, General Activity scale; SF-36 Bodily Pain scale; Roland-Morris Disability Questionnaire)
Number of subjects: 759
Study 28176175 — intervention group
Group type: EXPERIMENTAL
Intervention: WT1-immunotherapeutic
Number of subjects: 62
Study 28176175 — intervention group
Group type: COMPARATOR
Intervention: Standard neoadjuvant therapy
Number of subjects: 62
Study 26612050 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental health literacy
Number of subjects: 1016
Study 25148876 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term music-based multitask exercise program (Jaques-Dalcroze eurhythmics)
Number of subjects: 52
Study 25148876 — intervention group
Group type: COMPARATOR
Intervention: Control group (discontinued participation)
Number of subjects: 52
Study 21893151 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-doses of PCV7(CRM197)
Number of subjects: 0
Study 21893151 — intervention group
Group type: EXPERIMENTAL
Intervention: 2+1-doses of PCV7(CRM197)
Number of subjects: 0
Study 21893151 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 20166437 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol determination method using LC-MS
Number of subjects: 0
Study 17449109 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower CBCL externalizing scores
Number of subjects: 91
Study 17449109 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower externalizing scores
Number of subjects: 91
Study 14706012 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholinergic therapy (bethanechol chloride 60 mg/day or distigmine bromide 15 mg/day)
Number of subjects: 119
Study 14706012 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-blocker therapy (urapidil 60 mg/day)
Number of subjects: 119
Study 14706012 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (cholinergic drug and alpha-blocker)
Number of subjects: 119
Study 14706012 — intervention group
Group type: COMPARATOR
Intervention: Cholinergic therapy (control)
Number of subjects: 119
Study 14706012 — intervention group
Group type: COMPARATOR
Intervention: Alpha-blocker therapy (control)
Number of subjects: 119
Study 11676116 — intervention group
Group type: EXPERIMENTAL
Intervention: Butenafine (1%) cream applied for 4 weeks for tinea pedis and 2 weeks for tinea cruris and tinea corporis
Number of subjects: 111
Study 11038765 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal (i.p.) carboplatin chemotherapy
Number of subjects: 10
Study 11038765 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (i.v.) carboplatin chemotherapy
Number of subjects: 10
Study 7946939 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral isosorbide dinitrate (ISDN; 20 mg twice daily for 2 weeks)
Number of subjects: 20
Study 7946939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3229341 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula 1 (patient group 1)
Number of subjects: 20
Study 3229341 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula 2 (patient group 2)
Number of subjects: 20
Study 31838920 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanate for 4 weeks and a short course of oral steroids
Number of subjects: 57
Study 31838920 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin for 8 weeks
Number of subjects: 57
Study 31838920 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate
Number of subjects: 57
Study 31838920 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin
Number of subjects: 57
Study 28727270 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg/day
Number of subjects: 620
Study 28727270 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 620
Study 26401752 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC) (30 to 45 seconds)
Number of subjects: 40
Study 26401752 — intervention group
Group type: COMPARATOR
Intervention: Immediate cord clamping (ICC) (5 to 10 seconds)
Number of subjects: 40
Study 25032112 — intervention group
Group type: EXPERIMENTAL
Intervention: marsupialisation + coblation
Number of subjects: 90
Study 25032112 — intervention group
Group type: COMPARATOR
Intervention: marsupialisation + electric coagulation
Number of subjects: 90
Study 25032112 — intervention group
Group type: EXPERIMENTAL
Intervention: marsupialisation + coblation + microsurgery
Number of subjects: 90
Study 24397123 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional center of tibial plateau as the entry point (Group A)
Number of subjects: 60
Study 24397123 — intervention group
Group type: COMPARATOR
Intervention: Digital technology using Mimics 10.01 software for tibial intramedullary positioning (Group B)
Number of subjects: 60
Study 19935070 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 600 mg
Number of subjects: 120
Study 19935070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 18079558 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic eccentric training and stretching of the Achilles and patellar tendons
Number of subjects: 209
Study 18079558 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic eccentric training and stretching of the patellar tendons
Number of subjects: 209
Study 18079558 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic eccentric training and stretching of the Achilles tendons
Number of subjects: 209
Study 18079558 — intervention group
Group type: EXPERIMENTAL
Intervention: Preseason ultrasonographic abnormalities in the tendons
Number of subjects: 209
Study 16272199 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-leg knee extensor exercise training for 6 weeks
Number of subjects: 11
Study 16272199 — intervention group
Group type: COMPARATOR
Intervention: Cuff occlusion with superimposed handgrip exercise
Number of subjects: 11
Study 16272199 — intervention group
Group type: COMPARATOR
Intervention: Baseline measurements (no intervention)
Number of subjects: 11
Study 16272199 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-training measurements (after exercise training)
Number of subjects: 11
Study 16272199 — intervention group
Group type: COMPARATOR
Intervention: Ischemic handgrip exercise after training
Number of subjects: 11
Study 12730925 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar resurfacing during primary total knee arthroplasty
Number of subjects: 0
Study 12730925 — intervention group
Group type: COMPARATOR
Intervention: Patellar retention during primary total knee arthroplasty
Number of subjects: 0
Study 11095598 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (single dose)
Number of subjects: 314
Study 11095598 — intervention group
Group type: COMPARATOR
Intervention: Tetracycline (6-week course, twice daily)
Number of subjects: 314
Study 9367292 — intervention group
Group type: EXPERIMENTAL
Intervention: True acupuncture
Number of subjects: 22
Study 9367292 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 22
Study 1454657 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 1.6 mg daily
Number of subjects: 40
Study 1454657 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisone 10 mg daily
Number of subjects: 40
Study 3922048 — intervention group
Group type: EXPERIMENTAL
Intervention: CaNa2EDTA infusion during the first 2 days after admission
Number of subjects: 0
Study 3922048 — intervention group
Group type: COMPARATOR
Intervention: Normal conservative treatment
Number of subjects: 0
Study 30352818 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating metabolites
Number of subjects: 4952
Study 30352818 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic variables for fourteen top metabolites
Number of subjects: 4952
Study 30352818 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolome
Number of subjects: 4952
Study 30019751 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative aspirin
Number of subjects: 603
Study 30019751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 603
Study 26418211 — intervention group
Group type: EXPERIMENTAL
Intervention: HiP (high protein): parenteral nutrition = 3.5 AA, enteral nutrition = 4.6 protein g·kg·day
Number of subjects: 164
Study 26418211 — intervention group
Group type: COMPARATOR
Intervention: StP (standard protein): parenteral nutrition = 2.5 AA, enteral nutrition = 3.6 protein g·kg·day
Number of subjects: 164
Study 26418211 — intervention group
Group type: EXPERIMENTAL
Intervention: HiP
Number of subjects: 164
Study 26418211 — intervention group
Group type: COMPARATOR
Intervention: StP
Number of subjects: 164
Study 24500579 — intervention group
Group type: EXPERIMENTAL
Intervention: Hinged external fixator (Compass Knee Hinge) for six weeks (Group B)
Number of subjects: 100
Study 24500579 — intervention group
Group type: COMPARATOR
Intervention: Ligament reconstruction with external hinged knee brace (Group A)
Number of subjects: 100
Study 24500579 — intervention group
Group type: EXPERIMENTAL
Intervention: Hinged external fixator (Group B)
Number of subjects: 100
Study 24500579 — intervention group
Group type: COMPARATOR
Intervention: External hinged knee brace (Group A)
Number of subjects: 100
Study 22958175 — intervention group
Group type: EXPERIMENTAL
Intervention: DRD2 A1(‐) allele and/or DAT 9R(+) allele in sustained male quitters
Number of subjects: 0
Study 22958175 — intervention group
Group type: COMPARATOR
Intervention: Control group (continuing smokers)
Number of subjects: 0
Study 22958175 — intervention group
Group type: EXPERIMENTAL
Intervention: DRD2 A1(+) allele and/or DAT 9R(‐) allele
Number of subjects: 0
Study 21155337 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine-fentanyl (3 mg of 0.1% levobupivacaine plus 10 microg of fentanyl)
Number of subjects: 60
Study 21155337 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine-fentanyl (18 mg of 0.6% lidocaine plus 10 microg of fentanyl)
Number of subjects: 60
Study 21155337 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine-fentanyl
Number of subjects: 60
Study 21155337 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine-fentanyl
Number of subjects: 60
Study 17602120 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional antipsychotics
Number of subjects: 0
Study 17602120 — intervention group
Group type: COMPARATOR
Intervention: Atypical antipsychotics
Number of subjects: 0
Study 15295694 — intervention group
Group type: EXPERIMENTAL
Intervention: Canarypox HIV‐1 vaccine
Number of subjects: 1497
Study 15295694 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1497
Study 11256873 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 69
Study 11256873 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 11256873 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT
Number of subjects: 69
Study 9831304 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (75 mg daily for 12 weeks)
Number of subjects: 12
Study 9831304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8085185 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help groups for relatives of schizophrenic patients
Number of subjects: 0
Study 8085185 — intervention group
Group type: COMPARATOR
Intervention: Control group (relatives not involved in self-help)
Number of subjects: 0
Study 2751143 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral medication (meperidine 3.0 mg/kg, pentobarbital 4.0 mg/kg)
Number of subjects: 67
Study 2751143 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular medication (morphine 0.1 mg/kg, pentobarbital 4.0 mg/kg)
Number of subjects: 67
Study 339373 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (Minipress; Pfizer)
Number of subjects: 24
Study 339373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 30948581 — intervention group
Group type: EXPERIMENTAL
Intervention: Messages sent on Tuesday
Number of subjects: 194
Study 30948581 — intervention group
Group type: EXPERIMENTAL
Intervention: Messages sent on Wednesday
Number of subjects: 194
Study 30948581 — intervention group
Group type: EXPERIMENTAL
Intervention: Messages sent on Thursday
Number of subjects: 194
Study 30948581 — intervention group
Group type: EXPERIMENTAL
Intervention: Messages sent on Friday
Number of subjects: 194
Study 30948581 — intervention group
Group type: COMPARATOR
Intervention: Messages sent on Monday
Number of subjects: 194
Study 29249224 — intervention group
Group type: EXPERIMENTAL
Intervention: MAKS therapy
Number of subjects: 362
Study 26378264 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower Extremity/Mobility Cerebral Palsy Computerized Adaptive Test (LE CP‐CAT)
Number of subjects: 255
Study 23074076 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RT) intervention for 8 weeks, 8 exercises, 1 set of 10 repetitions at perceived exertion of 5-6, performed twice a week
Number of subjects: 25
Study 23074076 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 25
Study 21110035 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncinectomy (n = 10)
Number of subjects: 20
Study 21110035 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural ostial dilatation (n = 10)
Number of subjects: 20
Study 19709691 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glucose infusion (0.75 g glucose per kilogram body weight for 2.5 hours)
Number of subjects: 16
Study 19709691 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 17583027 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (12 family groups, 15 professionals)
Number of subjects: 149
Study 17583027 — intervention group
Group type: COMPARATOR
Intervention: Control group (12 family groups, 14 professionals)
Number of subjects: 149
Study 15716204 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg daily for 4 weeks, followed by flexible dosing (5 mg or 10 mg)
Number of subjects: 1802
Study 15716204 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin treatment
Number of subjects: 1802
Study 12072586 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg lercanidipine
Number of subjects: 40
Study 12072586 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg lercanidipine
Number of subjects: 40
Study 12072586 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg or 20 mg lercanidipine
Number of subjects: 40
Study 12072586 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 10086838 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg reboxetine orally
Number of subjects: 12
Study 10086838 — intervention group
Group type: COMPARATOR
Intervention: 0.3 mg reboxetine as an intravenous bolus
Number of subjects: 12
Study 7985892 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine, 600 mg/d
Number of subjects: 1001
Study 7985892 — intervention group
Group type: COMPARATOR
Intervention: Zalcitabine, 2.25 mg/d
Number of subjects: 1001
Study 7985892 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine, 600 mg/d, and zalcitabine, 2.25 mg/d
Number of subjects: 1001
Study 7985892 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (zidovudine and zalcitabine)
Number of subjects: 1001
Study 7985892 — intervention group
Group type: COMPARATOR
Intervention: Zalcitabine
Number of subjects: 1001
Study 7985892 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups (for patients with 50 to 150 CD4 cells/mm3 or fewer than 50 CD4 cells/mm3)
Number of subjects: 1001
Study 7985892 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with 150 or more CD4 cells/mm3
Number of subjects: 1001
Study 2154407 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (initial dose, long-term treatment for 1 and 6 weeks)
Number of subjects: 13
Study 2154407 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (after first dose)
Number of subjects: 13
Study 2154407 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (after 1 week)
Number of subjects: 13
Study 2154407 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (after 6 weeks)
Number of subjects: 13
Study 2154407 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 380178 — intervention group
Group type: EXPERIMENTAL
Intervention: diethylpropion hydrochloride (Tenuate)
Number of subjects: 40
Study 380178 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study 31809270 — intervention group
Group type: EXPERIMENTAL
Intervention: LA‐PM&R
Number of subjects: 2222
Study 31809270 — intervention group
Group type: COMPARATOR
Intervention: Control (non-participants)
Number of subjects: 2222
Study 31816842 — intervention group
Group type: EXPERIMENTAL
Intervention: Euglena gracilis fermentate (BG) 367 mg
Number of subjects: 34
Study 28062085 — intervention group
Group type: EXPERIMENTAL
Intervention: ThuLEP
Number of subjects: 208
Study 28062085 — intervention group
Group type: COMPARATOR
Intervention: TURis
Number of subjects: 208
Study 25816702 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS reminder system for OGTT at six weeks postpartum with further reminders at three and six months if required.
Number of subjects: 276
Study 25816702 — intervention group
Group type: COMPARATOR
Intervention: Control group received one text reminder at six months postpartum.
Number of subjects: 276
Study 25816702 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS reminder system for OGTT at six weeks postpartum.
Number of subjects: 276
Study 24216113 — intervention group
Group type: EXPERIMENTAL
Intervention: Affected meridian acupuncture group (n = 107)
Number of subjects: 428
Study 24216113 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-affected meridian acupuncture group (n = 107)
Number of subjects: 428
Study 24216113 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive sham acupuncture group (n = 107)
Number of subjects: 428